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The threat of antibiotic resistance has attracted strong interest during the last
two decades, thus stimulating stewardship programs and research on alternative
antimicrobial therapies. Conversely, much less attention has been given to the
directly related problem of resistance toward antiseptics and biocides. While bacterial
resistances toward triclosan or quaternary ammonium compounds have been
considered in this context, the bis-biguanide chlorhexidine (CHX) has been put into focus
only very recently when its use was associated with emergence of stable resistance to
the last-resort antibiotic colistin. The antimicrobial effect of CHX is based on damaging
the bacterial cytoplasmic membrane and subsequent leakage of cytoplasmic material.
Consequently, mechanisms conferring resistance toward CHX include multidrug efflux
pumps and cell membrane changes. For instance, in staphylococci it has been shown
that plasmid-borne qac (“quaternary ammonium compound”) genes encode Qac efflux
proteins that recognize cationic antiseptics as substrates. In Pseudomonas stutzeri,
changes in the outer membrane protein and lipopolysaccharide profiles have been
implicated in CHX resistance. However, little is known about the risk of resistance toward
CHX in oral bacteria and potential mechanisms conferring this resistance or even cross-
resistances toward antibiotics. Interestingly, there is also little awareness about the risk
of CHX resistance in the dental community even though CHX has been widely used
in dental practice as the gold-standard antiseptic for more than 40 years and is also
included in a wide range of oral care consumer products. This review provides an
overview of general resistance mechanisms toward CHX and the evidence for CHX
resistance in oral bacteria. Furthermore, this work aims to raise awareness among the
dental community about the risk of resistance toward CHX and accompanying cross-
resistance to antibiotics. We propose new research directions related to the effects of
CHX on bacteria in oral biofilms.
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INTRODUCTION
The 2016 Review on Antimicrobial Resistance has predicted an
alarming scenario that the number of annual deaths attributable
to antimicrobial resistance will increase globally from the current
700,000 to 10 million in the year 2050 (O’Neill, 2016). In this
light, resistance toward antibiotics has attracted strong interest
in the scientific as well as the medical community during the
last few decades, and provided a major stimulus for establishing
stewardship programs (Allerberger et al., 2009) and in the search
for alternative antimicrobial measures such as antimicrobial
peptides, natural compounds, cold atmospheric plasma, or light-
based approaches (Karygianni et al., 2015; Czaplewski et al.,
2016; Wainwright et al., 2017; Cieplik et al., 2018a). Furthermore,
the oral cavity has recently been highlighted as a potential
reservoir of antibiotic resistance genes that can be transferred
via horizontal gene transfer among the bacteria present in oral
biofilms (Roberts and Mullany, 2010; Al-Ahmad et al., 2014;
Jiang et al., 2018).
Conversely, much less attention has been paid to the
directly related problem of resistance toward the different
classes of antiseptics and biocides (Forman et al., 2016; Kampf,
2016; Venter et al., 2017). This is somewhat surprising as
bacterial resistance toward commonly used antiseptics such
as benzalkonium chloride (BAC; a quaternary ammonium
compound, QAC), triclosan (TCS; a polychloro phenoxy phenol)
and chlorhexidine (CHX), as well as induction of cross-
resistances between these agents and a range of clinically
important antibiotics, have been known for many years
(Yamamoto et al., 1988; McDonnell and Russell, 1999; Stickler,
2002; Russell, 2004; Yazdankhah et al., 2006).
While TCS has already been banned from its use in household
wash products by the FDA in 2016 due to its risk of triggering
cross-resistances (McNamara and Levy, 2016) and resistance
toward QACs like BAC has also been highlighted in numerous
reports (e.g., Buffet-Bataillon et al., 2012; Jaglic and Cervinkova,
2012), CHX has come into the spotlight only recently (Kampf,
2016; Venter et al., 2017; Wand et al., 2017). For example, it
was reported that exposure to CHX may be associated with
emergence of stable resistance to the last-resort antibiotic colistin,
which may be associated with mutations in the two-component
regulator phoPQ (Wand et al., 2017). The lack of focus on
CHX resistance is somewhat surprising since it was found as
early as 1980 that the extensive and liberal use of CHX in
the management of patients with long-term bladder catheters
resulted in urinary tract infections from CHX-resistant Gram-
negative bacteria (i.e., strains of Proteus mirabilis, Providencia
stuartii, and Pseudomonas aeruginosa), which were also found
to be multidrug-resistant (Stickler and Thomas, 1980; Stickler,
2002). More recently, a high prevalence of reduced susceptibility
toward CHX (69%) was found in microorganisms that caused
central line-associated bloodstream infections in a large academic
medical center with significantly higher proportion in patients
who received daily CHX bathing (86% vs. 64%; p = 0.028)
(Suwantarat et al., 2014).
Interestingly, the use of CHX in the field of dentistry for
oral biofilm control has not been considered so far in this
context as a possible source for the development of resistance
against CHX itself or cross-resistances against other antiseptics
or antibiotics (Sreenivasan and Gaffar, 2002). This is in spite of
the widespread use of CHX by dental clinicians as gold-standard
antiseptic (Jones, 1997), e.g., for plaque control and managing
gingivitis (Van der Weijden et al., 2015) or for treatment of
periodontitis (Teughels et al., 2009). In addition, CHX is included
in a wide range of oral care consumer products (Sanz et al., 2013;
Cieplik et al., 2018b).
Therefore, the objectives of this work are to review
the evidence for resistance in oral bacteria toward CHX
and to summarize our understanding of potential resistance
mechanisms toward CHX. This review further aims to raise
awareness among the dental community about the potential
risk of resistance toward CHX as well as concomitant cross-
resistances toward antibiotics and to propose future research
directions related to CHX resistance in oral bacteria.
CHEMISTRY AND HISTORICAL
ASPECTS
Chlorhexidine is a symmetric bis-biguanide molecule comprising
two chloroguanide chains that are connected by a central
hexamethylene chain and carries two positive charges at
physiological pH (see Figure 1A for structural formula). It acts
as a strong base and is practically insoluble in water but reacts
with acids to form salts that exhibit varying water solubility
characteristics (Davies et al., 1954; Denton, 2001; Lim and Kam,
2008). Today, mostly the digluconate or diacetate salts are used,
whereby the water solubility of CHX digluconate is considerably
higher than that of CHX diacetate (50% w/v vs. 2% w/v) (Kampf,
2018b). For the sake of clarity, in the present paper the acronym
CHX will be used for all of its salts.
Chlorhexidine was first synthesized in Great Britain in the
early 1950s within the scope of a broad screening exercise for
active agents against malaria by Imperial Chemical Industries
(Manchester, United Kingdom) (Lim and Kam, 2008; Kampf,
2016). It was described by Davies et al. (1954) under the name
“Hibitane R©” as “a new antibacterial agent of high potency” using
its diacetate and dihydrochloride salts to ensure water solubility.
Since then CHX has extensively been used in various medical
fields (e.g., urology, gynecology, ophthalmology, otolaryngology)
as well as for disinfection of surgical environments before it was
introduced to dentistry in the late 1960s (Gjermo, 1974).
ANTIBACTERIAL MECHANISM OF
ACTION
In general, it is often difficult to distinguish the primary
mechanism of action of a given antiseptic or biocide from
secondary effects that are merely a consequence of the action
(Maris, 1995). CHX is usually described to act as a bacteriostatic
agent at low concentrations and to be bactericidal at higher
concentrations (Jones, 1997). Its antibacterial mechanism of
action is described as damage of bacterial membranes and
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FIGURE 1 | (A) Chemical structural formula of CHX digluconate. (B) Scanning electron microscopic (SEM) visualization of an in vitro polymicrobial biofilm comprising
Actinomyces naeslundii, Actinomyces odontolyticus, and S. mutans (methodology as described in Cieplik et al., 2018b,c) following treatment with CHX (0.2%;
10 min). Vesicle-like structures on the surfaces of bacterial cells indicate membrane damage (indicated by red arrows). SEM images are reprinted from Cieplik et al.
(2018b). (C–F) Scheme depicting the mode of action of CHX toward bacterial cytoplasmic membranes. The bacterial cytoplasmic membrane carries a net negative
charge and is composed of a phospholipid bilayer with embedded proteins. The phospholipid bilayer is stabilized by divalent cations such as Ca2+ and forms a
hydrophobic environment, which is essential to moderate the functionality of the embedded proteins (C). CHX (as a cationic agent) binds to the negatively charged
bacterial cell surface and initially interacts with the cytoplasmic membrane. Thereby, CHX bridges between pairs of phospholipid headgroups and displaces the
associated divalent cations (D). Progressive decrease in fluidity of the outer phospholipid layer with creation of hydrophilic domains within the bilayer affecting the
osmoregulation and metabolic activity of the cytoplasmic membrane and its associated enzymes (E,F). This scheme was adopted and modified from
Gilbert and Moore (2005).
subsequent leakage of cytoplasmic components (see Figure 1B
for scanning electron microscopic images of CHX-mediated
damage to bacterial cell surfaces) (McDonnell and Russell, 1999;
Gilbert and Moore, 2005). First-line targets of CHX (at lower
concentrations) are cytoplasmic membrane integrity as well
as function of membrane-bound enzymes (see Figures 1C–F
for a scheme describing the detailed interaction of CHX with
bacterial cytoplasmic membranes), while secondary effects (at
higher concentrations) are cytoplasmic leakage and, ultimately,
coagulation and precipitation of intracellular constituents such
as proteins and nucleic acids (Denyer and Stewart, 1998;
McDonnell and Russell, 1999; Gilbert and Moore, 2005). As
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cytoplasmic membranes are the main action sites of CHX,
the outer membrane in Gram-negative bacteria may act as a
permeability barrier for CHX and limit its antibacterial efficacy.
For instance, cationic CHX molecules may be “locked up”
in the outer membrane due to interactions with negatively
charged lipopolysaccharide-moieties and thus may not be able
to even reach the cytoplasmic membrane (Cheung et al., 2012).
Furthermore, outer membrane vesicles released by Gram-
negative bacteria like Porphyromonas gingivalis may bind CHX,
thus allowing protection of bacteria (Grenier et al., 1995). As
there is not much data on the actual role or influence of the outer
membrane in Gram-negative bacteria with regard to the action of
CHX, this point merits closer attention.
Studies of the effects of CHX at sub-inhibitory, bacteriostatic,
concentrations are very scarce. Analogous to QACs or antibiotics
at sub-inhibitory concentrations, the effects of CHX at such
concentrations may be far more complicated including
multiple processes such as loss of osmoregulation around
the cytoplasmic membrane, disturbance of processes related
to transport and respiratory activity, dissipation of proton
motive force and oxidative stress, which triggers SOS responses
and in turn induces error-prone DNA replication leading to
mutations and gene transfers (Andersson and Hughes, 2014;
Tezel and Pavlostathis, 2015).
RESISTANCE MECHANISMS
Intrinsic resistance is defined as natural property of an
organism, while acquired resistance is resulting from genetic
changes and arising either by mutation or by the acquisition
of the genetic material, e.g., via plasmids (Russell, 1995).
Furthermore, one has to clearly distinguish between phenotypic
adaptation, which is reversible when the exposure to the agent
ends, and acquired resistance, which is genetically defined
and therefore stable (Meyer and Cookson, 2010). Resistance
must also be differentiated from tolerance, whereby resistance
means the inherited ability of microorganisms to survive
high concentrations of an antimicrobial drug (quantified by
the minimum inhibitory concentration, MIC), while tolerance
describes the ability to withstand a transient exposure to high
concentrations of an antimicrobial (which otherwise would be
lethal) without a change in MIC mostly due to the deceleration
of metabolic processes (Brauner et al., 2016). In contrast,
persistence describes the presence of a sub-population that is
able to survive a treatment with concentrations higher than
the MIC of a given antimicrobial despite the population being
clonal (Brauner et al., 2016). These terms have often been used
synonymously in the literature (especially in older studies), which
hampers differentiation.
Furthermore, the definition of “resistance” toward antiseptics
is not entirely clear (Chapman, 2003; Sheldon, 2005; Maillard,
2007). There are internationally recognized and standardized
methods for susceptibility testing of antibiotics with defined
breakpoints by means of which given isolates can be classified
as resistant, intermediate or susceptible. This practically means
that given isolates whose MIC values exceed the breakpoint
concentrations are deemed resistant to a given antibiotic
(Chapman, 2003). In contrast, similar frameworks are missing
for susceptibility testing of biocides like CHX and there is a
lack of well-defined MIC cut-off values indicating resistance
(Vijayakumar and Sandle, 2018). While in vitro methods
originally developed for systemic antibiotics (e.g., MICs) are
still used for antiseptics, their results must be interpreted
with caution (Sheldon, 2005). In this context, measurable MIC
increases by a given factor (often 4- to 16-fold) have been
considered relevant and may be seen as a parallel definition of
“resistance” (Chapman, 2003), while on the other hand “in-use”
concentrations of these biocides may be much higher than the
measured MICs (Maillard, 2007; Vijayakumar and Sandle, 2018).
Despite these limitations, investigation of MICs can still
be valuable for antiseptics for studying potential resistance
mechanisms in vitro (Maillard, 2007).
Intrinsic resistance to CHX is known from bacterial spores
and mycobacteria and is due to their outer cell layers which
form an impermeable barrier to the ingress of CHX molecules
(Horner et al., 2012). Acquired genetically defined mechanisms
conferring resistance toward CHX include multidrug efflux
pumps and cell membrane changes (Jaglic and Cervinkova, 2012;
Kampf, 2018b). The latter have been suspected to be responsible
for CHX resistance in Pseudomonas stutzeri, where changes
in the outer membrane protein and lipopolysaccharide profiles
were found in CHX-resistant strains as compared to CHX-
sensitive ones (Tattawasart et al., 2000b). Accordingly, electron-
microscopic investigations confirmed that treatment with CHX
led to considerably greater morphological changes in CHX-
sensitive cells, while CHX-resistant cells showed no structural
damage. Furthermore, it was confirmed by energy-dispersive
spectroscopy that there was less uptake of CHX in resistant cells
(Tattawasart et al., 2000a). The CHX-resistant strains also showed
decreased susceptibility toward different classes of antibiotics
which was suggested to be due to a non-specific decrease in cell
permeability limiting uptake of chemically unrelated molecules
into the resistant cells (Tattawasart et al., 1999).
Multidrug efflux pumps are membrane proteins that contain
multiple transmembrane domains forming channels to remove
toxic substances from the cytoplasm and the cytoplasmic
membrane (see Figure 2 for schematic depiction of two
exemplary efflux systems conferring CHX resistance in Gram-
positive or Gram-negative bacteria, respectively) (Wassenaar
et al., 2015). For instance, the plasmid-borne qac (standing for
“quaternary ammonium compound”) gene family (e.g., qacA,
qacB, qacC; qacA, and qacB usually recorded as qacA/B and
qacC synonymously termed smr) is well known in Gram-positive
bacteria (mainly in staphylococci). These qac genes encode
for Qac efflux proteins that belong to the “Major Facilitator
Superfamily” (MFS, i.e., QacA/B) or to the “Small Multidrug
Resistance” (SMR) family (i.e., Smr) and have cationic biocides
like CHX as substrates (Littlejohn et al., 1991; Poole, 2007;
Buffet-Bataillon et al., 2012; Jaglic and Cervinkova, 2012; Liu
et al., 2015; Kampf, 2016). Accordingly, introduction of a CHX-
based surface antiseptic protocol in an intensive care unit with
methicillin-resistant Staphylococcus aureus (MRSA) prevalence
of about 20% was found to lead to an immediate and sustained
Frontiers in Microbiology | www.frontiersin.org 4 March 2019 | Volume 10 | Article 587
fmicb-10-00587 March 21, 2019 Time: 17:24 # 5
Cieplik et al. Resistance Toward Chlorhexidine in Oral Bacteria
FIGURE 2 | Efflux mechanisms conferring resistance toward CHX. A common resistance mechanism toward antibacterial agents such as CHX is up-regulation of
multidrug efflux pumps. This scheme shows two well-known efflux systems, i.e., qacA in Gram-positive S. aureus and mexAB-oprM in Gram-negative P. aeruginosa.
These efflux pumps may also be present in oral bacteria and recognize not only CHX as their substrate but also other antiseptics and antibiotics, and, thus, may
contribute to cross-resistances between CHX and antibiotics. This scheme was adopted and modified from Venter et al. (2017).
reduction in transmission of susceptible MRSA strains while
strains carrying qacA/B genes were not affected after introduction
of this protocol (Batra et al., 2010). In contrast, a recent study
found no correlation in S. aureus isolates between susceptibility
toward CHX and carriage of qacA/B genes (Hardy et al., 2018).
Interestingly, when comparing two pairs of isolates with fourfold
differences in susceptibility to CHX (as shown by minimum
bactericidal concentrations, MBCs) but very close relation
according to phylogeny data, single-nucleotide polymorphisms
within chromosomal efflux systems encoded by norA or norB
were identified indicating that norA/norB may functionally
complement qacA/qacB in these strains (Hardy et al., 2018).
In Gram-negative bacteria, efflux proteins from the SMR
family (e.g., QacE, QacE11, QacF, QacG) and from the
“Resistance-Nodulation-Division” (RND) superfamily (like the
Mex efflux systems in P. aeruginosa) have been described (Poole,
2007; Liu et al., 2015). For instance, the activity of the MexCD-
OprJ multidrug efflux system was found to be upregulated in
P. aeruginosa upon exposure to sub-inhibitory concentrations
of CHX or BAC (Morita et al., 2014). Expression of this efflux
gene was found in various mutants, suggesting that MexCD-
OprJ is a determinant of CHX resistance (Fraud et al., 2008).
Furthermore, the four RND superfamily efflux pumps MexAB-
OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM are
also well recognized to confer resistance to fluoroquinolones
(Morita et al., 2014). Likewise, the “Proteobacterial Antimicrobial
Compound Efflux” (PACE) family is wide-spread in Gram-
negative bacteria conferring resistance to a wide range of biocides
(Hassan et al., 2018) whose first member, the active CHX efflux
protein AceI, was identified by investigating the transcriptomic
response in Acinetobacter baumannii toward CHX (Hassan et al.,
2013). In the same study, it was also found that expression of the
RND efflux protein AdeAB was even more up-regulated upon
CHX exposure (Hassan et al., 2013).
The close association frequently found between antibiotic
and antiseptic resistance may be explained by the fact that
genetic determinants of resistance are commonly linked to
each other; accordingly, the qac genes are frequently located
on plasmids with various other resistance genes (Jaglic and
Cervinkova, 2012). For example, a clinical strain of S. aureus
with high-level resistance to vancomycin isolated in June
2002 harbored a 57.9 kb multi-resistance conjugative plasmid,
pLW1043, comprising elements that encode for resistance toward
vancomycin (vanA), trimethoprim (dfrA), β-lactams (blaZ),
aminoglycosides (aacA-aphD) as well as antiseptics (qacC)
(Weigel et al., 2003). Likewise, the plasmid pSAJ1 from a
methicillin- and gentamicin-resistant strain of S. aureus isolated
in the 1980s conferred resistance toward CHX (most likely due
to qacA) along with resistance toward kanamycin, gentamicin,
tobramycin, amikacin, BAC, acriflavine, and ethidium bromide
(Yamamoto et al., 1988).
Recently, it was found that adaptation of clinical Klebsiella
pneumoniae isolates to CHX in vitro can lead not only
to stable resistance toward CHX but also cross-resistance
toward the last line antibiotic colistin (Wand et al., 2017).
Whole genome sequencing revealed mutations in phoPQ
and/or smvR, whereby the smvR mutation in turn may
lead to upregulation of smvA which encodes for expression
of SmvA, an efflux pump belonging to the MFS, which
was suggested to play a major role in CHX resistance of
K. pneumoniae strains. The cross-resistance toward colistin upon
adaptation to CHX was likely due to the mutation in PhoPQ
affecting the regulatory targets pmrD and pmrK. The operon
pmrK functions to alter lipopolysaccharides by replacement
of phosphate groups by 4-amino-4-deoxy-L-arabinose, which
in turn reduces the net negative charge of lipid A and
results in a reduction of its binding affinity to colistin
(Wand et al., 2017).
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EVIDENCE FOR RESISTANCE TOWARD
CHX IN ORAL BACTERIA?
Chlorhexidine has been extensively used in dental practice since
1970, when Löe and Schiøtt (1970) described total inhibition
of plaque formation and gingivitis development in patients
applying a 0.2% CHX mouth rinse twice daily despite stopping all
other oral hygiene measures (e.g., tooth brushing) (see Gjermo,
1974). Already in 1972 two studies were published reporting
clinical isolates of Streptococcus sanguinis that showed slightly
reduced susceptibility toward CHX after long-term use of CHX-
containing mouth rinses, which was, however, considered to
be “relatively inconspicuous” (Emilson et al., 1972; Schiøtt and
Löe, 1972). Isolates of S. sanguinis with reduced susceptibility
to CHX were also found in a later clinical study upon daily
tooth brushing with 0.5% CHX-containing gel, whereby the
authors concluded that it was unclear whether this finding was
a result of an adaptation toward CHX or due to a selection
for less sensitive mutants within the original oral microbiota
(Emilson and Fornell, 1976).
Westergren and Emilson (1980) described adaptation to
CHX in three CHX-sensitive strains of S. sanguinis when grown
in vitro as continuous cultures in a fermenter containing medium
with increasing CHX concentrations. This resistance persisted
after continuous growth in CHX-free medium and, interestingly,
extracted DNA from the resistant mutants transformed
competent sensitive S. sanguinis strains to increased CHX
resistance. Therefore, they concluded that appearance of less
susceptible isolates in the oral cavity after long-term use of CHX
may be explained by genetic changes and not solely by selection
for naturally occurring less susceptible strains (Westergren and
Emilson, 1980). Likewise, when screening 315 isolates from
subgingival plaque for their susceptibility to a mouth rinse
containing 0.2% CHX, evidence for what the authors called
“relative resistance” in different strains of Streptococcus mitis,
S. sanguinis, and Capnocytophaga spp., was found (Wade and
Addy, 1989). Maynard et al. (1993) reported significantly higher
MICs for CHX in bacteria recovered from patients that had been
using a 1% CHX toothpaste for 6 months as compared to those
using a toothpaste without CHX. However, this finding was not
thought to be of clinical significance (Maynard et al., 1993).
Passaging 24 periodontitis-associated bacteria (i.e., 10
oral streptococci, 8 P. gingivalis strains, 4 Aggregatibacter
actinomycetemcomitans strains, and 2 enterobacteria) on agar
plates containing sub-inhibitory concentrations of CHX resulted
in a transitory moderate increase in the tolerance to CHX in
five of the tested isolates (i.e., 1 oral streptococcus strain, 3
P. gingivalis strains, and 1 A. actinomycetemcomitans strain) after
25 passages, which vanished again after 50 passages in spite of
the agar still containing sub-inhibitory concentrations of CHX
(Eick et al., 2011). Kulik et al. (2015) reported two- to fourfold
increased MICs in two out of five P. gingivalis strains after
culturing for 20–30 passages in sub-inhibitory concentrations
of CHX, whereas no increase in MIC was observed for two
Streptococcus mutans and two Streptococcus sobrinus strains.
Recently, Kitagawa et al. (2016) found that repeated exposure
of Enterococcus faecalis to CHX by serial passaging (10 cycles
of exposure to CHX for MIC testing followed by re-growth
in CHX-free medium) resulted in continuous increase in its
MIC. The adapted cells showed increased surface hydrophobicity.
Furthermore, SDS-PAGE of the adapted mutant strain revealed a
novel protein of about 19-kDa (Kitagawa et al., 2016) that had
also been found in vancomycin-resistant enterococci (Cho et al.,
2008). The authors searched the proteome of E. faecalis 62 in the
NCBI database for a candidate protein and reported that the most
relevant protein in the 19-kDa range with regard to resistance was
a 19.93-kDa MFS efflux pump protein (Kitagawa et al., 2016).
This protein is unusually small for an MFS transporter and it
is not clear whether it directly exports vancomycin. However, it
is noteworthy that the candidate protein is a partial match to a
larger 45-kDa MFS protein of E. faecalis V583, encoded by ef2068
(Yan et al., 2015; Kitagawa et al., 2016).
Wang et al. (2017a) evaluated changes in MIC in eight
common oral bacterial species over 10 passages of CHX-challenge
and re-growth in CHX-free medium and reported adaptation
in Streptococcus gordonii, E. faecalis, Fusobacterium nucleatum,
and P. gingivalis. Further analysis of the adapted S. gordonii
strain showed a delayed growth with prolonged log-phase and
decelerated growth rate as compared to its parental strain
indicating reduced metabolic activity that may be responsible for
the reduced susceptibility toward CHX (Wang et al., 2017a).
In another recent study, bacteria were isolated from dental
plaque from five healthy individuals to screen for strains
resistant toward CHX (Saleem et al., 2016). CHX-resistant
isolates also displayed variable resistance to a range of antibiotics
including ampicillin, kanamycin, gentamicin and tetracycline.
Exposure of the most resistant isolate, a strain identified as
Chryseobacterium indologenes, to CHX (16 µg/mL) resulted in
a 19-fold up-regulation of the gene CIN01S_RS05745 encoding
expression of the HlyD-like periplasmic adaptor protein of a
tripartite efflux pump. However, it was not investigated whether
the other components of this efflux pump were upregulated
as well (Saleem et al., 2016). The authors highlighted the
requirement for increased vigilance for the presence of multidrug
resistant bacteria within dental plaque and raised awareness
of the potential risk of long-term use of oral care products
containing antimicrobial agents such as CHX for the control
of oral biofilms.
Interestingly, treatment with CHX has also been shown to
induce the formation of antifungal-tolerant persister cells in
Candida albicans biofilms in vitro (LaFleur et al., 2006). In
another study, 150 isolates of C. albicans and Candida glabrata
obtained from cancer patients, who were at high risk for the
development of oral candidiasis and who had been treated
with topical CHX once a day, were investigated in terms
of the development of persisters (LaFleur et al., 2010). The
authors found that persister cells are clinically relevant and
that antimicrobial therapy with CHX and long-term carriage
of Candida select for high-persister strains in vivo. There are
also reports of the induction of S. mutans persisters by CHX in
single-species biofilms (Wang et al., 2017b).
The increased clinical use of CHX makes it important to
be alert to the possibility of the emergence of new clones
with reduced susceptibility (Horner et al., 2012). It seems
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reasonable that microorganisms will be exposed to sub-inhibitory
concentrations of antiseptics in a clinical environment (Block
and Furman, 2002). Such sub-inhibitory concentrations can be
reached in the oral cavity upon treatment with CHX, as the
antimicrobial effect of CHX seems to be diminished in the
presence of organic substance such as saliva or serum due to
inactivation by salivary or serum proteins (Portenier et al., 2006;
Abouassi et al., 2014). Also inside oral biofilms, treatment with
CHX results in a concentration gradient from the biofilm surface
toward its lower strata which may lead to biofilm layers with
sub-inhibitory concentrations of CHX (Thurnheer et al., 2003).
Accordingly, the limited antimicrobial effects of CHX in the
inner layers of oral biofilms have been shown using confocal
laser scanning microscopy in combination with LIVE/DEAD
staining (see Figure 3) (Zaura-Arite et al., 2001; Karygianni
et al., 2014; Al-Ahmad et al., 2016). Furthermore, starvation
may play a major role in these biofilms, which may increase
FIGURE 3 | 3D-reconstruction of a LIVE/DEAD-stained confocal image stack
of a supragingival oral biofilm after treatment with CHX. The biofilm was
formed in situ on a bovine enamel slab for 72 h (methodology as described in
Al-Ahmad et al., 2015) and was either left untreated (A) or was treated with
0.2% CHX for 5 min (B). Bacteria with intact (green; considered “live”) or
compromised bacterial membranes (red; considered “dead”) are depicted
indicating “pockets of viable cells” within the biofilm.
adaptation of the bacteria within the biofilm. It was shown
that S. mutans exhibited significantly increased MBCs toward
CHX under starvation conditions in vitro than in nutrient-rich
medium (Tong et al., 2011).
CONCLUSION AND FUTURE
DIRECTIONS
The question, whether there already is reason for concern with
regard to enhanced tolerance or even resistance toward CHX
in oral bacteria, cannot be answered that easily and must be
treated in a more differentiated way: On the one hand, CHX
is still very effective in its various fields of clinical application,
e.g., intensive care, hand soaps and as an oral antiseptic. On the
other hand, there unquestionably are reports about emergence
of isolates exhibiting enhanced tolerance toward CHX. True
resistance toward CHX will have horrendous consequences for
infection control. For example, Copin et al. (2019) recently
reported the spread of a unique USA300 clone of community-
acquired MRSA in an Orthodox Jewish Community in Brooklyn.
Genetic analyses showed that a metabolic change (mutation
in pyrA) and acquisition of a clone-specific prophage (811)
probably have primed the clonal variant for success by promoting
colonization and abscess formation. However, it was also
found that emergence of a dominant clone coincided with
acquisition and evolution of a plasmid (pBSRC1) with genes
conferring resistance to CHX (qacA/B) and mupirocin (mupA),
strongly suggesting that resistance toward antimicrobials used
for decolonization therapy like CHX and mupirocin were key
elements in the spread of this clone (Copin et al., 2019).
Moreover, low level exposure to CHX (as potentially occurring in
deeper layers of oral biofilms) may result in development of cross-
resistances toward antibiotics as it has already been described
in biocide-sensitive strains from organic foods (Kampf, 2018a).
As there currently is little awareness about the potential risks
FIGURE 4 | Multiple passaging of bacteria under CHX-treatment in vitro. MICs of CHX, cetylpyridinium chloride (CPC) and methacryloyloxydodecylpyridinium
bromide (MDPB) repeatedly performed from passages 0–10 (P0–P10) against E. faecalis. This figure is reprinted from Kitagawa et al. (2016) with kind permission
from the publisher.
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accompanying the widespread use of CHX in dentistry, this
research subject should be particularly highlighted as a hot topic
in dental research. From the authors’ point of view, there are two
key questions relating to CHX resistance that urgently need to
be addressed:
• Does the widespread use of CHX lead to an enrichment
of resistant strains in oral biofilms and does it further
encourage the development of cross-resistances in
oral biofilms?
• What are the molecular mechanisms conferring CHX
resistance in oral bacteria?
The emergence of resistant bacteria as a result of the
widespread use of CHX in dental practice has not been studied
systematically so far. Culturing biofilms in oral in situ biofilm
models and treating them with CHX sequentially would give
insights into ecological changes of the microbiota of the oral
biofilm after long-term treatment with this antimicrobial agent.
In this light, it will be important to analyze the impact of CHX by
microbiome analyses by high-throughput sequencing methods as
well as by culture techniques that can distinguish between viable
and non-viable cells. In addition, subsequent testing of antibiotic
resistance in representative oral isolates may facilitate the study
of potential effects of CHX on cross-resistance toward antibiotics
and emergence of multidrug resistant bacteria. What remains
unclear is the clinical relevance of persister cells in oral biofilms
which have frequently been treated with CHX. The research on
persister development in oral bacteria under the pressure of CHX
treatment is still in its early stage.
Furthermore, novel techniques like transposon sequencing
(Tn-seq) are now available that can be used to identify key genetic
mechanisms of CHX resistance in oral bacteria by determining
gene disruptions differentially represented in mutant
populations on a genome-wide scale (van Opijnen et al., 2009;
Burby et al., 2017). For this purpose, resistant strains must either
be isolated from patient samples or induced in vitro by multiple
passaging of bacteria under CHX-treatment (see Figure 4),
whereby the latter has the advantage that the mutant strain
exhibiting phenotypic adaptation to CHX can be compared to the
wildtype strain. Finally, it is important to consider the respective
fitness cost of a given mutation related to CHX resistance as
the magnitude of this cost is the main biological parameter
determining the rate of development of resistance (Andersson
and Hughes, 2010; Cai et al., 2017).
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